GH-IGF1 peptides: the clinical evidence gap

A 2026 narrative review published in Frontiers in Endocrinology set out to map the distance between what clinical trials actually show about peptides targeting the growth-hormone (GH) and insulin-like growth factor-1 (IGF-1) axis, and what people who self-administer those same peptides believe they are doing^[1]. The authors, a team from Poznan University of Medical Sciences, found that the gap is wide and largely unacknowledged in the online communities where dosing protocols circulate.

This article explains what the review found, why the GH-IGF1 axis is the target of so many performance compounds, and what the actual clinical data does and does not support. It covers CJC-1295, sermorelin, ipamorelin, GHRP-2, GHRP-6, and related agents. It does not tell you how to use any of them.

Why the GH-IGF1 axis attracts so much attention

Growth hormone, produced by the pituitary gland, drives a downstream signalling cascade that ends with insulin-like growth factor-1 production in the liver. IGF-1 then acts on muscle, bone, and fat tissue. Reduced GH and IGF-1 output is a normal feature of aging, and that decline is associated with increased body fat, reduced lean mass, and lower bone density. The only GHRH analogue with US approval, tesamorelin, is authorised solely for HIV-associated lipodystrophy, not for healthy aging or performance.

That biology is real and well-characterised. The question the Frontiers review asks is whether the peptides marketed to address that decline in healthy adults without a diagnosed GH deficiency actually do what their proponents claim, and at what cost^[1].

The two main categories of peptide involved

The review divides the field into two functional classes. The first is GHRH analogues: synthetic versions of growth-hormone-releasing hormone, which is the signal the hypothalamus sends to the pituitary to prompt GH release. Sermorelin, tesamorelin, and CJC-1295 sit in this class. The second is GH secretagogues (also called GHRPs or ghrelin mimetics): peptides that act on a separate receptor, the growth-hormone secretagogue receptor (GHSR), to amplify GH release through a complementary pathway. Ipamorelin, GHRP-2, GHRP-6, and hexarelin are in this class.

The two classes are often combined in self-administration protocols on the assumption that the effects are additive. The review notes that this is biologically plausible but that the combination has not been systematically tested in controlled human trials for performance or physique outcomes. For the regulatory picture in each jurisdiction, see the CJC-1295 regulation pages and the ipamorelin regulation pages.

What the human clinical evidence actually shows

The strongest human data in this area belongs to CJC-1295. A 2006 double-blind, placebo-controlled trial by Teichman and colleagues enrolled healthy adults and measured GH and IGF-1 responses after single and repeated injections^[3]. The results showed dose-dependent increases in mean plasma GH concentrations of two- to ten-fold, sustained for six days or more after a single injection. IGF-1 levels rose to 1.5 to 3 times baseline and remained elevated for nine to eleven days.

That pharmacokinetic profile is genuinely distinctive: the modification that gives CJC-1295 its long half-life (measured at 5.8 to 8.1 days in the Teichman study^[3]) was engineered by ConjuChem to let the peptide bind plasma albumin and circulate for days rather than the minutes characteristic of native GHRH. But the Teichman study measured hormone levels, not clinical outcomes. Body composition, muscle strength, bone density, and recovery time were not primary endpoints.

The ConjuChem clinical programme stalled after 2006. No Phase 2 or Phase 3 efficacy trial of CJC-1295 for any indication in healthy adults has been completed and published in a peer-reviewed journal. Ipamorelin is in a similar position: characterised pharmacokinetically and shown to stimulate GH release selectively, but with no published controlled efficacy trial^[1].

What the Frontiers review found about self-administration

The Poznan team reviewed online self-administration protocols and found a consistent pattern: doses are often higher than those used in the available clinical pharmacology studies, cycles are longer, and compounds are combined in stacks that have never been tested together in humans^[1]. The review also found that product quality in the grey-market supply chain is poorly characterised, meaning that a vial labelled CJC-1295 may contain a different peptide, a degraded version, or contamination.

The adverse effects the review catalogues include fluid retention, joint pain, elevated blood glucose, carpal tunnel symptoms, and fatigue. These are known from therapeutic GH use; the extent to which they apply to lower-dose GH-secretagogue use in healthy adults is not established.

The sports-medicine perspective

A 2026 primer in the American Journal of Sports Medicine reviewed injectable peptide therapies for orthopaedic and sports medicine physicians^[2]. The authors found that CJC-1295 and ipamorelin showed improved muscle function in murine glucocorticoid-induced muscle-loss models, but stated plainly that this evidence is limited to animal studies with no human orthopaedic data supporting clinical use. The review concluded that 'information regarding the indications, dosing, frequency, and duration of treatment remains unknown.'

Regulatory and anti-doping status

None of the GH-secretagogue peptides in the Frontiers review are approved for performance or physique use anywhere. The World Anti-Doping Agency (WADA) prohibits GHRH analogues and GH secretagogues under Section S2 of the Prohibited List. CJC-1295 is explicitly listed as a prohibited substance. The FDA has not approved any of these compounds for use in healthy adults; the only GHRH analogue with US approval is tesamorelin (Egrifta), authorised solely for HIV-associated lipodystrophy.

In the EU, no marketing authorisation exists for CJC-1295, ipamorelin, sermorelin, GHRP-2, or GHRP-6. Products sold online as these compounds are sold outside the regulated medicines framework, which means no quality control, no pharmacovigilance, and no confirmed active-ingredient assay unless the buyer commissions independent testing.

What the clinical framework proposed by the authors covers

The Frontiers review concludes with a clinical assessment algorithm designed for physicians who encounter patients already using these compounds^[1]. The algorithm does not legitimise off-label use; it is intended to help clinicians interpret abnormal laboratory results, recognise adverse effects, and counsel patients on risk without dismissing the conversation.

The authors recommend baseline and monitoring measurements of IGF-1, fasting glucose, HbA1c, and thyroid function when patients report using GH-axis peptides.

What to take from this

The GH-IGF1 axis is a legitimate physiological target. The pharmacology of GHRH analogues and GH secretagogues is real, and the hormone-level effects in small clinical studies are measurable. What is not established is whether those hormone-level effects translate into meaningful improvements in muscle mass, body composition, recovery speed, or longevity in healthy adults^[1][3]. No large-scale controlled trial has tested that question.

The full regulatory and evidence picture for CJC-1295 is on its peptide page, including the WADA prohibition and the country-by-country legal status. If you are a clinician managing a patient who is using these compounds, the Frontiers review is a reasonable starting point for the laboratory work-up discussion.

This article is for educational purposes only. It does not constitute medical advice. Consult a healthcare provider before making any decisions about your health or treatment.